Orforglipron beats oral semaglutide on HbA1c in 1,698-patient phase 3
Tolerability was the trial's key sticking point, with the daily pill also producing greater weight loss than oral semaglutide over 52 weeks.
MH
By Maren Holt · Senior Reporter, GLP-1
Jul 8 03:00 ETSource: ScienceDaily
The wire
- 01In a 52-week phase 3 trial of 1,698 adults with type 2 diabetes across six countries, orforglipron cut HbA1c by 1.71 to 1.91 percentage points from a baseline of 8.3%, versus 1.47 points for oral semaglutide.
- 02Orforglipron needs no food or water restrictions, unlike oral semaglutide, which must be taken on an empty stomach with a 30-minute wait, a practical difference for adherence.
- 03Participants on orforglipron lost 6.1 to 8.2 kg versus 5.3 kg on semaglutide, but the report flags tolerability as a key issue raised by the trial.
From the source
Read at sciencedaily.comNew weight loss pill beats oral Ozempic in major trial
A new type of daily pill has proven more effective for weight loss and blood sugar control for people with type 2 diabetes than its currently available counterparts, according to a recent trial. The drug, known as orforglipron, could be a game-changer in the rapidly expanding oral weight-loss drug market.